NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Monday reported a loss of $87.3 million in its third quarter.
On a per-share basis, the Novato, California-based company said it had a loss of $1.74.
The results topped Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $1.94 per share.
The biotechnology company posted revenue of $11.8 million in the period, which also topped Street forecasts. Nine analysts surveyed by Zacks expected $11.2 million.
Ultragenyx shares have increased 14 percent since the beginning of the year. In the final minutes of trading on Monday, shares hit $53.10, a climb of 7 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE
Automated Insights, source Associated Press News